

DAFTAR PUSTAKA

- [1] Van Leuven SI, Kastelein JJP. Atorvastatin. *Expert Opin Pharmacother*. 2005;6(7):1191-1203.
- [2] Aini N, Saraswati RD, Oktoberia IS. Profil Disolusi Terbanding, Penetapan Kadar, dan Kualitas Fisik Tablet Atorvastatin Inovator, Generik Bernama Dagang, dan Generik. *Jurnal Kefarmasian Indonesia*. 2015;5(2):90-97.
- [3] Fadil DA, Rusdiana T, Muchtaridi. Pengaruh Kompleksasi Inklusi Atorvastatin dengan β -siklodekstrin terhadap Formulasi dan Evaluasi Fast Disintegrating Tablets (FDT) Atorvastatin. *Media Farmasi*. 2016;13(2):155-72.
- [4] Insull W. Comparison of Efficacy and Safety of Atorvastatin (10 mg) with Simvastatin (10 mg) at Six Weeks. *Am J Cardiol*. 2001;87(5):554-559.
- [5] Nawrocki JW, Weiss SR, Davidson MH. Reduction of LDL Cholesterol by 25% to 60% in Patients with Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor. *Arterioscler Thromb Vasc Biol*. 1995;15(5):678-82.
- [6] Lennernäs H. Clinical Pharmacokinetics of Atorvastatin. *Clin Pharmacokinet*. 2003;42(13):1141-60.
- [7] Utami S. Patentabilitas Antibakteri dari Tanaman *Garcinia* (*Antibacterials Patentability of Plant Garcinia*). *Jurnal Kedokteran YARSI*. 2016;24(1):69-79.
- [8] Lee S, Kim H. Adverse Effects of Atorvastatin: Myopathy and Beyond. *Korean J Med*. 2019;94(3):210-25.
- [9] Dachriyanus, Asjar NS, Susanti M. Determination of *Rubraxanthone* in the Latex of Asam Kandis (*Garcinia cowa Roxb*) by Reverse Phase High Performance Liquid Chromatography. *Pharmacogn J*. 2017;9(2):288-91.
- [10] Susanti M, Darmianti R, Harahap Y, Itam A, Hamidi D. Single Dose Oral Pharmacokinetic Profile of *Rubraxanthone* in Mice. *Heliyon*. 2022;8(3):1-6.
- [11] Wahyu W, Sodik A, Miyarso C, Widiatuti TC. Profil Penggunaan Obat Tradisional oleh Konsumen Apotek Karanganyar. *Jurnal Farmasi Komunitas*. 2024;11(2):108-112.
- [12] Tulunay M. Herbal Medicine Use Among Patients with Chronic Diseases. *J Intercult Ethnopharmacol*. 2015;4(3):217-220.

- [13] Thomas AB. Pharmacokinetics and Pharmacodynamic Herb Drug Interaction of Piperine with Atorvastatin in Rats. *J Chromatogr Sci*. 2021;59(4):371-80.
- [14] Bailey DG. Grapefruit–medication interactions: forbidden fruit or avoidable consequences *CMAJ*. 2013;185(4):309–316.
- [15] Sopian A, Imansari ANR. *Biofarmasetika dan Farmakokinetika*. 2024. 1-139.
- [16] Xia B. UHPLC–MS/MS Method for Determination of Atorvastatin Calcium in Human Plasma. *J Pharm Biomed Anal*. 2018;159:272–9.
- [17] Jisha U. Mastering Bioanalytical Sample Preparation Techniques: Achieving Accurate Analysis. *Int J Pharm Sci*. 2024;2(8):3806-3821.
- [18] Annissa S, Musfiroh I, Indriati L. Perbandingan Metode Analisis Instrumen HPLC dan UHPLC. *Farmaka*. 2020;17(3):189-194.
- [19] Cielecka J. UHPLC: The Greening Face of Liquid Chromatography. *Chromatographia*. 2013;76(22):1429-437.
- [20] Susanti M. Pengujian Profil Farmakokinetika Rubrasanton yang Diisolasi dari Kulit Batang Asam Kandis *Garcinia cowa* Roxb setelah Pemberian secara Oral pada Mencit. Andalas University; 2019.
- [21] Alen Y, Safitri N, Dachriyanus, Ali AM, Ladjis NH SM V. Rubraxhantone dari *Garcinia forbesii* King dan Bioaktivitasnya. 2008;1(2):192–201.
- [22] Trinh DH, Ha LD, Tran PT, Nguyen LHD. Isoprenylated *Xanthone* and Benzophenone Constituents of the Pericarp of *Garcinia planchonii*. *Nat Prod Commun*. 2014;9(12):1737–40.
- [23] Alkadi KAA, Adam A, Taha M, Hasan MH, Shah SAA. Prenylated *Xanthone* and *Rubraxanthone* with Antiplatelet Aggregation Activity in Human Whole Blood Isolated from *Garcinia griffithii*. *Orient J Chem*. 2013;29(4):1291-5.
- [24] Ersam T, Kurniawan NR. Isolasi Senyawa Rubrasanton dan Parvifolisanton C dari Ekstrak Kulit Batang *Garcinia tetrandra* Pierre. *J Sains dan Seni ITS*. 2018;7(1):2337-3520.

- [25] Pattalung P, Wiriyaচিত্রা P, Ongsakul M. The Antimicrobial Activities of *Rubraxanthone* Isolated from *Garcinia parvifolia*. *Journal of the Science Society of Thailand*. 1988;14(2):67-71.
- [26] Ee GCL, Daud S, Izzaddin SA RM. *Garcinia mangostana*: A Source of Potential Anti-Cancer Lead Compounds Against CEM-SS Cell Line. *J Asian Nat Prod Res*. 2008;10(5):475-9.
- [27] Hismiatiy S. Teknik Ekstraksi Senyawa Aktif dari Bahan Alam. Jakarta: Universitas Indonesia Press; 2011.
- [28] Sastrohamidjojo H. Kromatografi. Yogyakarta: Liberty; 2002.
- [29] Tanaka K. Organic Chemistry: Recrystallization Methods and Techniques. Tokyo: Springer; 2009.
- [30] Harborne JB. Metode Fitokimia: Penuntun Cara Modern Menganalisis Tumbuhan. Bandung: ITB Press; 1987.
- [31] Ling SK, Chan PP, Choo CY. Isolation, Purification and Identification of Chemical Constituents from *Elateriospermum tapos*. *Malaysian Journal of Analytical Sciences*. 2006;10(1):1-6.
- [32] Pinninti VS. Atorvastatin as an Antihyperlipidemic Drug: A Comprehensive Review. *Int J Innov Res Technol*. 2024;11(7):3872-3873.
- [33] Stancu CS, Sima AV. Statins: Mechanism of Action and Effects. *J Cell Mol Med*. 2001;5(4):378-387.
- [34] PubChem. Atorvastatin. National Center for Biotechnology Information.
- [35] Sher M, Hussain G, Hussain MA, Akhtar T, Akram MR, Paracha RN, Murtaza G. Development and Validation of High-Performance Liquid Chromatographic-Ultraviolet (HPLC-UV) Method for the Bioequivalence Study of Atorvastatin. *Afr J Pharm Pharmacol*. 2012;6(32):2424-2428.
- [36] Porwal PK, Talele GS. Development of Validated Bioanalytical HPLC-UV Method for Simultaneous Estimation of Amlodipine and Atorvastatin in Rat Plasma. *Indian J Pharm Sci*. 2015;77:742-750.

- [37] Khan IU, Jillani SMS, Ashfaq M. Determination of Atorvastatin and Gemfibrozil in Human Plasma by Reversed-Phase Liquid Chromatography. *Lat Am J Pharm.* 2010;29:1383-1388.
- [38] Hansen SH BS. Bioanalysis of Pharmaceuticals Sample Preparation, Separation Techniques, and Mass Spectrometry. *Chicaster*; 2015.
- [39] Sherwood L. Fisiologi Manusia: Dari Sel ke Sistem Edisi Kedua. Jakarta: Penerbit Buku Kedokteran EGC; 1996.
- [40] Poedjaji A. Dasar-dasar Biokimia. Jakarta: UI Press; 1994.
- [41] Ahmed F, Eticha T, Hymete A, Ashenef A. Principles and Applications of Ultra-High-Performance Liquid Chromatography. In: High Performance Liquid Chromatography-Recent Advances and Applications. *IntechOpen*; 2023.
- [42] Kakade PS, Kandekar V. Comparative Study of HPLC and UHPLC. *World J Pharm Pharm Sci.* 2022;11(7):1702-9.
- [43] Gandjar IG, Rohman A. Kimia Farmasi Analisis. Yogyakarta: Pustaka Belajar; 2007.
- [44] Susanti M, Dachriyanus. Kromatografi Cair Kinerja Tinggi. Padang: LPTIK Universitas Andalas; 2017.
- [45] Putra E. Kromatografi Cair Kinerja Tinggi dalam Bidang Farmasi. Sumatra Utara: USU; 2004.
- [46] Kupicc. Quality-Control Analytical Methods: High-Performance Liquid Chromatography. *Int J Pharm Compd.* 2004;8(3):223-7.
- [47] Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography (3rd ed.). *Hoboken (NJ)*; 2010.
- [48] Suprianto. Parameter Optimasi dan Validasi Metode Ultra Fast Liquid Chromatography. 2023.
- [49] EMEA. Guideline on Bioanalytical Method Validation. 2012;44:1-23.
- [50] Johnson EL, Stevenson R, PPDK. Dasar Kromatografi Cair. Bandung: ITB Press; 1991.

- [51] Poedjaji A. Dasar-dasar Biokimia. Jakarta: UI Press; 1994.
- [52] Faranita T, Trisnawati Y, Lubis M. Cardiovascular Diseases. *Sari Pediatri*. 2011;13(3):226-32.
- [53] Ugochukwu JI, Ajaegbu EE, Chukwu nwejim CR, Uzochukwu IC. FTIR and UV-Visible Spectrophotometric Derivatization Studies of Artemether. *Adv Res*. 2020;21(10):25–31.
- [54] Ainil Mardyah. Optimasi dan Validasi Metode Analisis Cowanin dalam Plasma Menggunakan Kromatografi Cair Kinerja Tinggi. Padang: Fakultas Farmasi Universitas Andalas; 2022.
- [55] Alamri RG. Development and Validation of Bioanalytical UHPLC-UV Method for Simultaneous Analysis of Unchanged Fenofibrate and Its Metabolite Fenofibric Acid in Rat Plasma. *Saudi Pharm J*. 2016;24(6):667–675.
- [56] Wahyuni S. Optimasi dan Validasi Metode Analisis Rubrasanton dalam Plasma Menggunakan Kromatografi Cair Kinerja Tinggi. Padang: Fakultas Farmasi Universitas Andalas; 2022.
- [57] El-Shaheny RN. Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometry Method for Simultaneous Determination of Amlodipine, Atorvastatin, and Ezetimibe in Human Plasma and Its Application to a Pharmacokinetic Study. *Future J Pharm Sci*. 2019;5(1):1-12.
- [58] Raasi KM, Spandana U, Rahaman SA. Analytical Method Development and Validation of Remdesivir in Bulk and Pharmaceutical Dosage Forms Using Reverse Phase High Performance Liquid Chromatography. *Int J Pharm Sci Clin Res*. 2021;1(2):282–329.
- [59] Nugroho, A. E., et al. (2021). An update on the anticancer activity of xanthone derivatives. *Pharmaceuticals*, **14**(11), 1144.
- [60] Pop CE. Bisphenol A analysis and quantification inconsistencies via HPLC-UV: A systematic with technical notes. *Discover Applied Sciences*. 2024;6:171.
- [61] Hamidi D, et al. High Performance Thin Layer Chromatography: Densitometry Method for Determination of *Rubraxanthone* in the Stem Bark Extract of *Garcinia cowa Roxb*. *Pharmacogn Res*. 2017;9(3):230-3.

- [62] Lichota A. Cytotoxic properties and complete nuclear magnetic resonance assignment of isolated xanthenes from the root of *Garcinia cowa Roxb.* *Molecules*. 2015;20(10):18215–18232.
- [63] Adeogun AI. Solvent effect on $n \rightarrow \pi^*$ and $\pi \rightarrow \pi^*$ transition of 9-fluorenone. *Afr J Biotechnol*. 2008;7(15):2736–2738.
- [64] Kurniawan RN. Isolasi Senyawa Rubrasanton dan Parvifolisanton C dari Ekstrak Kulit Batang *Garcinia tetrandra Pierre*. *Jurnal Sains dan Seni ITS*. 2018;7(1):C10.
- [65] Santoni A, Syukri D, Rahmi A. Kajian Bioaktivitas Daun Sungkai (*Peronema canescens* Jack). Surabaya: Uwais Inspirasi Indonesia; 2023.
- [66] Agilent Technologies. *The LC Handbook: Guide to LC Columns and Method Development*. USA: Agilent Technologies; 2016.
- [67] El-Bagary RI, Elkady EF, El-Sherif ZA, Kadry AM. LC–MS–MS Simultaneous Determination of Atorvastatin and Ezetimibe in Human Plasma. *J Chromatogr Sci*. 2013;1–8.
- [68] Wahyuni S. Optimasi Preparasi Ekstraksi Cair-Cair Rubrasanton dalam Plasma -Analisis Menggunakan KCKT. Padang: Fakultas Farmasi Universitas Andalas; 2023.
- [69] Christopher J. Welch, Brkovic T, Schafer W, Gong X. Re-evaluating the choice of acetonitrile as the platform solvent for analytical HPLC. *Green Chem*. 2009;11(8):1232–1238.
- [70] Nováková L, Vlčková H, Solich P. Evaluation of new mixed-mode UHPLC stationary phases and the importance of stationary phase choice when using low ionic-strength mobile phase additives. *Talanta*. 2012;93:99–105.
- [71] Epshtein NA. System suitability requirements for liquid chromatography methods: controlled parameters and their recommended values (review). *Pharm Chem J*. 2020;54(5):518–525.
- [72] Li W, Jian W, Fu Y. *Sample Preparation in LC-MS Bioanalysis*. Vol. 1, Educacao e Sociedade. USA: John Wiley & Sons, Ltd; 2019.

- [73] Zhou Y, Li J, He X, et al. Simultaneous determination of atorvastatin and its metabolites in human plasma by UPLC–MS/MS. *Anal Methods*. 2017;9:114-123.
- [74] Bichala PK, et al. Development and validation of LC-MS/MS method for determination of atorvastatin in human plasma. *Asian J Med Health Sci*. 2021.
- [75] Stern RH, Yang BB, Hounslow NJ, MacMahon M, Abel RB, Olson SC. Pharmacodynamics and pharmacokinetic–pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. *J Clin Pharmacol*. 2000;40(6):616–623.
- [76] Calvano CD, Monopoli A, Cataldi TRI, Palmisano F. Matrix effects in liquid chromatography–mass spectrometry: overview of the main approaches for their evaluation and mitigation. *Molecules*. 2020;25(13):3047.
- [77] Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC–MS/MS. *Anal Chem*. 2003;75(13):3019–3030.
- [78] Dolan JW. HPLC Gradient Elution: Baseline Drift. *LCGC North America*. 2006;24(9):898–901.
- [79] Beyaz A, Fan W, Carr PW, Schellinger AP. Instrument parameters controlling retention precision in gradient elution reversed-phase liquid chromatography. *J Chromatogr A*. 2014;1371:90-105.
- [80] Talluri MVNK, Kalyankar TM, Rao RN. Synchronized separation of atorvastatin and its combined formulations by RP–LC. *J Saudi Chem Soc*. 2013;17(3):291–302.
- [81] Snyder LR, Stadalius MA, Quarry MA. Gradient elution in reversed-phase high-performance liquid chromatography. *Anal Chem*. 1983;55(14):1412A–1430A.